Locks of Love Report issue

Foundation Phase 2

Organization Overview

First Clinical Trial
2013
NCT01950780
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (2)

ruxolitinib (jakafi) (1 trial)

tofacitinib (xeljanz) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alopecia (Phase 2)

Alopecia Areata (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2